



Goldman Sachs – European Medtech and Healthcare Services Conference 2007


September 5/6, 2007



Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Achieving Profitable Growth in Attractive Health Care Segments



Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE

Fresenius Group: Accomplishments H1 2007

- Strong operating performance in all business segments
- Encouraging Biotech clinical trial results
- Conversion into a European Company (SE)
- New management and reporting structure for HELIOS and VAMED
- Increased earnings guidance


Fresenius Group: Excellent Financial Results

	Sales	EBIT	Net income
H1 2007	€ 5,592 m	€ 780 m	€ 195 m
Growth at constant currency rates	+ 15 %	+ 20 %	+ 44 %
Growth at actual currency rates	+ 10 %	+ 15 %	+ 39 %

Fresenius Kabi: Leading Market Positions in Infusion Therapy and Clinical Nutrition

- Significant growth in emerging markets
- Focus on organic growth and on selective acquisitions
- Market dynamics support mid-term 6-8 % organic sales growth and 16-18 % EBIT margin

Global production and distribution network



Status: August 2007

- Sales + marketing organizations
- ▲ Production sites
- R&D centers

Fresenius Kabi: 130 bps EBIT Margin Improvement Compared to H1 2006

€m	H1 2007	H1 2006	Growth
Sales	986	937	5 % (7 % organic)
EBIT	159	139	14 %
EBIT margin	16.1 %	14.8 %	
Net income	87	60	45 %

Fresenius Kabi: 2007 Financial Outlook Fully Confirmed

Guidance

Organic revenue
growth

6 – 8 %

EBIT margin

16.0 – 16.5 %

HELIOS Kliniken: Top-Tier Private Hospital Operator in Germany

- Germany is Europe's largest hospital market (> € 60 bn market size)
- Only 11% of German acute hospital beds managed by private operators
- Significant German hospital privatization opportunity
- HELIOS has a strong track record in hospital operations and acquisitions: targeting 15% EBITDA margin within 5 years per individual location

Source:

DKG – German Hospital Federation (2004)

Federal Statistical Office Germany (2004) Healthcare expenses adjusted to OECD's definition



Fresenius ProServe: 60 bps EBIT Margin Improvement Compared to H1 2006

€m	H1 2007	H1 2006	Change
Sales	1,069	974	10 % (2 % organic)
EBIT	75	62	21 %
EBIT margin	7.0 %	6.4 %	
Net income	31	23	35 %

Fresenius ProServe: 2007 Earnings Outlook Raised

Guidance

Organic revenue growth	2 – 3 %
EBIT	 ~ € 170 m

Fresenius Biotech: Update

- Secondary endpoints of phase II/III malignant ascites study confirm clear benefits from treatment with removab[®]
- Partnering process for trifunctional antibody removab[®] in North America and Japan ongoing
- Submission of malignant ascites dossier to EMEA end of 2007 expected
- 2007 EBIT outlook of ~ € -50 m confirmed

Fresenius Group: Unique Opportunities in All Business Segments

Fresenius Medical Care

Market leader in attractive North American market; International segment with superior growth and profitability; Renal drug expansion opportunity

Fresenius Kabi

Superior growth resulting from leading emerging markets position and successful core market product initiatives

Fresenius ProServe

Two-pronged strategy to benefit from significant German hospital privatization opportunity through leading hospital operations and outsourcing project management presence

Fresenius Biotech

Attractive growth option based on proprietary antibody technology

Fresenius Group: 2007 and Mid-term Outlook

2007 outlook

Guidance

Revenue growth
at constant currency

8 – 10 %

Net income growth
at constant currency

~25 %

Mid-term outlook

Revenue/EBIT margin

15/15 by 2010
Revenues of € 15 bn, EBIT margin of 15 %

Attachments



Fresenius Group: Strong Sales and EBIT Growth in all Business Segments


H1 2007	Fresenius Medical Care	Fresenius Kabi	Fresenius ProServe
Sales Growth	US\$ 4,725 m +21 %	€ 986 m +5 %	€ 1,069 m +10 %
EBIT Growth	US\$ 756 m +23 %	€ 159 m +14 %	€ 75 m +21 %

Fresenius Kabi: Sales H1 2007 – Fully in Line with Guidance

€m	H1 2007	H1 2006	Growth
Total Sales	986	937	7 %
By Product Segment:			
Infusion Therapy	529	513	4 %
Clinical Nutrition	398	365	11 %
Transfusion Technology	59	59	1 %

Fresenius Kabi: Organic Sales Growth of 7 %

Sales growth H1 2007 compared to H1 2006



Regional Sales €m	H1 2007	H1 2006	Growth	Organic Growth
Germany	213	214	0 %	0 %
Europe ex Germany	461	440	5 %	5 %
Asia-Pacific	145	122	19 %	22 %
Latin America	66	61	8 %	10 %
RoW	101	100	1 %	11 %
Total sales	986	937	5 %	7 %

Fresenius Kabi: 130 bps EBIT Margin Improvement Compared to H1 2006

€m	H1 2007	H1 2006	Change
EBIT	159	139	14 %
EBIT margin	16.1 %	14.8 %	
EBIT by Region:			
Europe	145	124	17 %
EBIT margin	21.5 %	19.0 %	
International	50	46	9 %
EBIT margin	16.0 %	16.3 %	
Corporate and Corporate R&D	-36	-31	-16 %
Net income	87	60	45 %

Fresenius ProServe: Sales Growth Fully in Line with Guidance

€m	H1 2007	H1 2006	Change	Organic
Sales	1,069	974	10 %	2 %
Sales by Division:				
Hospital Operations (HELIOS)	890	767	16 %	3 %
Engineering + Services for hospitals (VAMED + Pharmatec)	179	207*	-14 %	-2 %
Order intake Engineering business	106	185*	-43 %	-35 %

* Including Pharmaplan

Fresenius ProServe: 60 bps EBIT Margin Improvement Compared to H1 2006

€m	H1 2007	H1 2006	Growth
EBIT	75	62	21 %
EBIT margin	7.0 %	6.4 %	
EBIT by Division:			
Hospital operations	68	56	21 %
EBIT margin	7.6 %	7.3 %	
Engineering + Services for hospitals	9	9*	-
EBIT margin	5.0 %	4.3 %	
Corporate costs	-2	-3	33 %

* Including Pharmaplan

Fresenius Group: Profit and Loss Statement

€m	Q2 2007	H1 2007	H1 2007 actual rates	YoY constant rates	Remarks H1 2007
Sales	2,825	5,592	+10 %	+15 %	7 % organic growth
EBIT	400	780	+15 %	+20 %	Strong 13.9 % EBIT margin
Interest result	-90	-185	+5 %	-1 %	Impact of RCG acquisition from Q2 06
Taxes	-111	-214	-4 %	-9 %	36 % tax rate; at bottom end of 2007 guid.
Net income	102	195	+39 %	+44 %	H1 06: incl. € 16 m one-time expenses
EPS (prefs) (€)	0.67	1.27	+38 %	+42 %	

Fresenius Group: Cash Flow


€m	Q2 2007	H1 2007	H1 2007 YoY	Remarks H1 2007
Cash flow	298	582	+24 %	Strong earnings growth
Change in Working capital	-32	-29	+70 %	
Operating Cash flow	266	553	+48 %	Margin: 9.9 %
Capex (net)	-165	-297	-39 %	Investing into growth
Cash flow (before acquisitions and dividends)	101	256	+60 %	
Acquisitions (net)	-99	-162	+95 %	
Dividends	-184	-188	-22 %	
Free Cash flow (after acquisitions and dividends)	-182	-94	+97 %	

Fresenius Group: Capex and Acquisitions – Investing into Growth

Capex by Business Segment

	H1 2007 €m	H1 2006 €m	Change %
Fresenius Medical Care	189	141	34
Fresenius Kabi	44	37	19
Fresenius ProServe	70	41	71
Corporate	1	6	-83
Group	304	225	35

Acquisitions by Region



Total: € 221 m

Fresenius Group: Debt and Interest Ratios

	June 30, 2007	Dec 31, 2006
Debt (€m)	5,909	5,872
Net debt (€m)	5,603	5,611
Net debt/EBITDA	2.9	3.0 [*]
EBITDA/Interest	5.3	4.6 [*]

* excl. gain and EBITDA from divested dialysis clinics and one-time expenses for refinancing, incl. RCG in Q1

Net debt/EBITDA



Financial Calender / Contact / Basic Share Information

Financial Calender

October 31, 2007

Report on 1st - 3rd quarters 2007

Contact

Birgit Grund
SVP Investor Relations Fresenius SE

Telephone: +49 6172 608-2485
e-mail: Birgit.Grund@fresenius.com

Further information and current news: <http://www.fresenius.com>

Basic Share Information

	Ordinary share	Preference share
Securities code no.	578 560	578 563
Ticker symbol	FRE	FRE3
ISIN	DE0005785604	DE0005785638
Bloomberg symbol	FRE GR	FRE3 GR
Reuters symbol	FREG.de	FREG_p.de